Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: A case report

被引:6
作者
Ntziora F. [1 ]
Euthimiou A. [2 ]
Tektonidou M. [1 ]
Andreopoulos A. [1 ]
Konstantopoulos K. [1 ]
机构
[1] University of Athens School of Medicine, First Department of Medicine, Laiko General Hospital, Athens
[2] Department of Neurology, Laiko General Hospital, Athens
关键词
West Nile Virus; Axonal Neuropathy; Herpes Virus Infection; Polyradiculoneuropathy; Acute Motor Axonal Neuropathy;
D O I
10.1186/1752-1947-5-563
中图分类号
学科分类号
摘要
Introduction. We present a case of an unusual clinical manifestation of Guillain-Barre syndrome following a pre-existing herpes virus infection. Although there have been several reports describing the co-existence of herpes virus infection and Guillain-Barre syndrome, we undertook a more in-depth study of the cross-reactivity between herpes viruses and recommend a follow-up study based on serology tests. Case presentation. A 39-year-old healthy Caucasian man with Guillain-Barre syndrome presented to our facility initially with sensory disturbance, followed by an atypical descending pattern of clinical progression. On physical examination, our patient showed hot and cold temperature sensory disturbance under the T4 vertebrae level, symmetrically diminished muscle power mainly to his lower limbs, blurred vision, a loss of taste and paresis and diminished reflexes of his lower limbs. Serology test results for common viruses on hospital admission were positive for cytomegalovirus immunoglobulin M, cytomegalovirus immunoglobulin G, herpes simplex virus immunoglobulin M, herpes simplex virus immunoglobulin G, Epstein-Barr virus immunoglobulin M, and varicella zoster virus immunoglobulin G, borderline for Epstein-Barr virus immunoglobulin G and negative for varicella zoster virus immunoglobulin M. At one month after hospital admission his test results were positive for cytomegalovirus immunoglobulin M, cytomegalovirus immunoglobulin G, herpes simplex virus immunoglobulin G, Epstein-Barr virus immunoglobulin G, varicella zoster virus immunoglobulin G, borderline for herpes simplex virus immunoglobulin M and negative for Epstein-Barr virus immunoglobulin M and varicella zoster virus immunoglobulin M. At his six month follow-up, tests were positive for cytomegalovirus immunoglobulin G, herpes simplex virus immunoglobulin M, herpes simplex virus immunoglobulin G, Epstein-Barr virus immunoglobulin G and varicella zoster virus immunoglobulin G and negative for cytomegalovirus immunoglobulin M, Epstein-Barr virus immunoglobulin M and varicella zoster virus immunoglobulin M. Conclusions: The clinical manifestation of Guillain-Barre syndrome in our patient followed a combined herpes virus infection. The cross-reactivity between these human herpes viruses may have a pathogenic as well as evolutionary significance. Our patient showed seroconversion at an early stage of Epstein-Barr virus immunoglobulin M to immunoglobulin G antibodies, suggesting that Epstein-Barr virus might have been the cause of this syndrome. Even if this case is not the first of its kind to be reported, it may contribute to a better understanding of the disease and the cross-reaction mechanisms of herpes virus infections. This case report may have a broader clinical impact across more than one area of medicine, suggesting that cooperation between different specialties is always in the patient's best interest. © 2011 Ntziora et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 12 条
  • [1] Hughes R.A., Cornblath D.R., Guillain-Barré syndrome, Lancet, 366, 9497, pp. 1653-1666, (2005)
  • [2] Hughes R.A.C., Sensory form of Guillain-Barre syndrome, Lancet, 357, (2001)
  • [3] Jacobs B.C., Koga M., Van Rijs W., Geleijns K., Van Doorn P.A., Willison H.J., Yuki N., Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome, J Neuroimmunol, 194, pp. 181-190, (2008)
  • [4] Perera V.N., Nachamkin I., Ung H., Patterson J.H., McConville M.J., Coloe P.J., Fry B.N., Molecular mimicry in Campylobacter jejuni: Role of the lipo-oligosaccharide core oligosaccharide in inducing anti-ganglioside antibodies, FEMS Immunology and Medical Microbiology, 50, 1, pp. 27-36, (2007)
  • [5] Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre acute syndrome, Lancet, 349, pp. 225-230, (1997)
  • [6] Shahar E., Current therapeutic options in severe Guillain-Barré syndrome, Clinical Neuropharmacology, 29, 1, pp. 45-51, (2006)
  • [7] Yu R.K., Usuki S., Ariga T., Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases, Infection and Immunity, 74, 12, pp. 6517-6527, (2006)
  • [8] Kaida K., Ariga T., Yu R.K., Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders: A review, Glycobiology, 19, pp. 676-692, (2009)
  • [9] Irie S., Saito T., Nakamura K., Kanazawa N., Ogino M., Nukazawa T., Ito H., Tamai Y., Kowa H., Association of anti-GM <sub>2</sub> antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection, Journal of Neuroimmunology, 68, 1-2, pp. 19-26, (1996)
  • [10] Sanders V.J., Felisan S.L., Waddell A.E., Conrad A.J., Schmid P., Swartz B.E., Kaufman M., Walsh G.O., De Salles A.A.F., Tourtellotte W.W., Presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction: Preliminary study, Archives of Neurology, 54, 8, pp. 954-960, (1997)